Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Gains Ahead of FDA Decision
- Piper Jaffray Stays Bullish on Mallinckrodt (MNK), Lifts PT to $112
- Nymox Pharma (NYMX) Ramps to Session Highs Following Fexapotide Phase 3 Data
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!